A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
CancerLymphoma
Interventions
DRUG

XL844

Gelatin capsules supplied as 5-mg, 25-mg, and 100-mg strengths; twice-weekly dosing.

DRUG

Gemcitabine

once-weekly 30-minute IV infusion

Trial Locations (2)

10021

Memorial Sloan-Kettering Cancer Center, New York

77030

M.D. Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Exelixis

INDUSTRY